• Collaboration leverages synergies of QIAGEN’s OmicSoft omics data through Evotec’s analysis platform PanHunter
• Customers accelerate target discovery decisions with high-quality multi-omic evidence, and expanded analysis capabilities

Hamburg, Germany, and Venlo, the Netherlands, 03 June 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to leverage QIAGEN’s OmicSoft Land Databases through Evotec’s PanOmics data access and analysis platform PanHunter. Combining comprehensive data sets with advanced analytics capabilities will enable enhanced multi-omics data insights, better disease understanding and more precise therapeutic interventions.

Omics data offers extensive insights into patient conditions, molecular biology, and disease causes. QIAGEN’s market-leading OmicSoft solution accelerates research discoveries in biotech and pharma with vast amounts of annotated Omics data. QIAGEN’s OmicSoft Land Databases comprise integrated collections of multi-omics data and metadata, so-called “Lands”, which have been curated and standardised from the largest public dataset repositories. Through these deeply-curated and unified datasets, data scientists avoid common pitfalls of data mining, and can focus on powerful target profiling and indication expansion efforts.

PanHunter is Evotec’s interactive, collaborative, and easy-to-use analysis software for biological data. The next-generation platform combines published and peer-reviewed or in-house developed statistical analysis algorithms with AI/ML capabilities and enables in-depth analysis across PanOmics data sets. PanHunter offers researchers the flexibility to examine a few entries or correlate millions of data points, while also enhancing insights by associating meta-information, reference data and chemical and structural information for compounds, and clinical data.

The collaboration provides QIAGEN’s and Evotec’s partners and clients with an option to integrate licensed data from OmicSoft Lands with other data sets and perform comprehensive data analysis through PanHunter, thus enhancing the functionality and value of both platforms.

Dr Matthias Evers, Chief Business Officer of Evotec, commented: “We are excited about the partnership with QIAGEN as it is a testament to both our companies’ commitment to empowering users with unparalleled data analysis capabilities. By seamlessly integrating our strengths, we are not only connecting software, but revolutionising how scientists harness the power of data.”

Jonathan Sheldon, EVP Digital Insights at QIAGEN, said: “We believe this partnership will enable our shared customers to realise the promise of better insights and faster outcomes through AI and machine learning, by using the combination of the world’s leading Omics database with Evotec’s unique platform.”

For further information, please follow this link to the PanHunter website or contact us via panhunter@evotec.com.

About QIAGEN Digital Insights
QIAGEN Digital Insights, the bioinformatics business of QIAGEN, is the leading provider of genomic and clinical knowledge, analysis and interpretation tools and services for scientists and clinicians, with over 25 years of experience in the industry, 90,000 users worldwide, over 100,000 citations in scientific papers, more than 3.5 million profiled patient cases and over 40 billion scientific data points. Further information on expertly curated genomic and clinical knowledge solutions as well as bioinformatics software and services for efficient data management, sharing and actionable insights can be found at http://digitalinsights.qiagen.com.

About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2023, QIAGEN employed approximately 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.